JP2021533197A5 - - Google Patents
Info
- Publication number
- JP2021533197A5 JP2021533197A5 JP2021529257A JP2021529257A JP2021533197A5 JP 2021533197 A5 JP2021533197 A5 JP 2021533197A5 JP 2021529257 A JP2021529257 A JP 2021529257A JP 2021529257 A JP2021529257 A JP 2021529257A JP 2021533197 A5 JP2021533197 A5 JP 2021533197A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- complex
- transferrin receptor
- complex according
- receptor antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025006544A JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713959P | 2018-08-02 | 2018-08-02 | |
| US62/713,959 | 2018-08-02 | ||
| PCT/US2019/044960 WO2020028841A1 (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating pompe disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006544A Division JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021533197A JP2021533197A (ja) | 2021-12-02 |
| JP2021533197A5 true JP2021533197A5 (enExample) | 2022-08-10 |
Family
ID=69230844
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529257A Pending JP2021533197A (ja) | 2018-08-02 | 2019-08-02 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
| JP2025006544A Pending JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006544A Pending JP2025071093A (ja) | 2018-08-02 | 2025-01-17 | ポンペ病を処置するための筋標的化複合体およびそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210317226A1 (enExample) |
| EP (1) | EP3830127A4 (enExample) |
| JP (2) | JP2021533197A (enExample) |
| KR (1) | KR20210054513A (enExample) |
| CN (2) | CN112912399A (enExample) |
| CA (1) | CA3108285A1 (enExample) |
| EA (1) | EA202190417A1 (enExample) |
| IL (1) | IL280483A (enExample) |
| WO (1) | WO2020028841A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018281280B2 (en) | 2017-06-07 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US20230330246A1 (en) * | 2020-05-05 | 2023-10-19 | Avidity Biosciences, Inc. | Compositions and methods of treating pompe disease |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| KR20230117182A (ko) | 2020-12-04 | 2023-08-07 | 다인 세라퓨틱스, 인크. | 항체-올리고뉴클레오티드 복합체 및 그의 용도 |
| EP4359534A4 (en) * | 2021-06-21 | 2026-07-22 | Dyne Therapeutics Inc | MUSCLE TARGETTING COMPLEXES AND THEIR USES IN THE TREATMENT OF POMPE DISEASE |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| CA3230796A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| WO2023122671A2 (en) * | 2021-12-22 | 2023-06-29 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing glycogen synthase 1 |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| IL318627A (en) * | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Anti-TFR charge fusions and methods of using them |
| US12527877B2 (en) | 2024-01-24 | 2026-01-20 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592143B2 (en) * | 2003-04-18 | 2009-09-22 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| AR100560A1 (es) * | 2014-05-23 | 2016-10-12 | Genzyme Corp | Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido |
| MY207684A (en) * | 2015-12-08 | 2025-03-12 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| US11060089B2 (en) * | 2016-04-18 | 2021-07-13 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| DK3473270T5 (da) * | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
-
2019
- 2019-08-02 EP EP19844183.4A patent/EP3830127A4/en active Pending
- 2019-08-02 CA CA3108285A patent/CA3108285A1/en active Pending
- 2019-08-02 EA EA202190417A patent/EA202190417A1/ru unknown
- 2019-08-02 WO PCT/US2019/044960 patent/WO2020028841A1/en not_active Ceased
- 2019-08-02 US US17/265,016 patent/US20210317226A1/en not_active Abandoned
- 2019-08-02 JP JP2021529257A patent/JP2021533197A/ja active Pending
- 2019-08-02 CN CN201980064590.5A patent/CN112912399A/zh active Pending
- 2019-08-02 CN CN202410663435.8A patent/CN118662653A/zh active Pending
- 2019-08-02 KR KR1020217005994A patent/KR20210054513A/ko not_active Ceased
-
2021
- 2021-01-28 IL IL280483A patent/IL280483A/en unknown
-
2025
- 2025-01-17 JP JP2025006544A patent/JP2025071093A/ja active Pending